Creative Medical Technologies, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Mar 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 24, 2027The maintenance fee for Generation of autologous immune modulatory cells for treatment of neurological conditions (US 11,795,433) comes due Apr 24, 2027. Unpaid by Oct 25, 2027, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 7 of 7
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,372,797 | Treatment of Erectile Dysfunction by Stem Cell Therapy In force · High confidence | In force | High confidence | |
| US 11,795,433 | Generation of autologous immune modulatory cells for treatment of neurological conditions In force · From the USPTO record | In force | From the USPTO record | |
| US 12,642,818 | Inducing and Accelerating Post-Stroke Recovery by Administration of Amniotic Fluid Derived Stem Cells In force · High confidence | In force | High confidence | |
| US 10,792,310 | Methods for treatment of premature ovarian failure and ovarian aging using regenerative cells In force · From the USPTO record | In force | From the USPTO record | |
| US 12,385,011 | Treatment of heart failure and/or post infarct pathological remodeling by ex vivo reprogrammed immune cells In force · From the USPTO record | In force | From the USPTO record | |
| US 12,391,925 | Prevention and/or treatment of type 1 diabetes by augmentation of myeloid suppressor cell activity In force · From the USPTO record | In force | From the USPTO record | |
| US 12,741,015 | Suppression of Diabetes Using Exosomes from Stem Cell Programmed Myeloid Cells In force · High confidence | In force | High confidence |
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
22 pending · 10 abandoned · 29 no status recorded